(Total Views: 67)
Posted On: 09/23/2019 11:15:21 AM
Post# of 85493
$CYDY CytoDyn
Annual shareholders meeting discussed Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
https://www.cytodyn.com/newsroom/press-releas...meeting-of
Annual shareholders meeting discussed Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
https://www.cytodyn.com/newsroom/press-releas...meeting-of
(0)
(0)
